UNITHER acquires UCB’s pharmaceutical plant in Rochester (USA)
UNITHER PHARMACEUTICALS, which is backed by Equistone and Parcom PE, has completed the acquisition of UCB’s pharmaceutical plant in Rochester (USA). Unither will continue to manufacture UCB products for the US market under the terms of the transaction. In an agreement reached in May 2013, Unither will also retain all 300 UCB employees.
This transaction is an important step in Unither’s strategy of international expansion and this acquisition in the USA is a step ahead from the approval by the Food and Drugs Administration (FDA) of its plant in Coutances, Normandy obtained in July 2011.
As well as continuing to manufacture products for UCB and other major US clients, Unither will deploy its Blow-Fill-Seal and stick-pack technologies in Rochester, in order to offer local production of both forms of dosage to its current and future US clients.
Eric Goupil, president of Unither Pharmaceuticals comments: “We are particularly proud of the confidence that UCB group has shown in Unither by entrusting us with the manufacture of their products for the American market. This is the recognition of the policy of excellence that we have adhered to in France since the group was established”
DEUTSCHLAND / SCHWEIZ
München & Zürich
- IWK Communication Partner
- Ira Wülfing / Florian Bergmann
- Tel: +49 (0)89 2000 30 30
- E-Mail IWK
- Agnès Catineau/Aurélia de Lapeyrouse
- Tel: +33 (0)1 53 96 83 83
- E-Mail Brunswick